Company: PTHS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001753926-25-000790
Chunk: 84

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 2
Chunk 84
---
, CT2000 and CT 3000,
and potentially other molecules, it is unlikely that the Company will generate product or licensing revenue during the next twelve
months. During the three months ended March 31, 2024, the Company completed its initial public offering, raising $5.7 million, after
deducting the underwriting discounts and commissions and offering expenses, and the Company
may need to raise additional funds through either strategic partnerships or the capital markets. However, there is no assurance
that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional
funds by issuing securities, existing stockholders may be diluted.

31

Results
of Operations

Comparison
of the Three Months Ended March 31, 2025 and 2024

The
following table summarizes our results of operations for the three months ended March 31, 2025 and 2024:

    Three
    Months Ended March 31, 2025 and 2024

    2025

    2024

    $
    Change

    %
    Change

    OPERATING
    EXPENSES

    General
    and administrative expenses
     
    $
    1,090,049

    $
    787,561

    $
    302,488

    38
    %

    Research
    and development

    194,298

    466,606

    (272,308
    )

    (58
    )%

    Professional
    fees

    549,630

    679,815

    (130,185
    ) 

    (19
    )%

    Total
    operating expenses

    1,833,977

    1,933,982

    (100,005
    ) 

    (5
    )%

    Loss
    from operations

    (1,833,977
    )

    (1,933,982
    )

    100,005

    (5
    )%

    Other
    expense

    (133,634
    )

    (628,348
    )

    494,714

    (79
    )%

    Net
    loss before provision for income taxes

    (1,967,611
    )

    (2,562,330
    )

    594,719

    (23
    )%